Achieving New Treatment Goals in Multiple Sclerosis: Strategies for Initial Treatment Selection and Patient Engagement
This live meeting took place on May 31, 2018.
An on-demand webcourse of the live meeting content will be available in July 2018.
A CME/CE-certified Symposium in conjunction with the 2018 Annual Meeting of the CMSC
Thursday, May 31, 2018
Breakfast and Registration: 6:30-7:00am (Breakfast courtesy of CMSC)
CME/CE Program: 7:00-8:00am
Nashville Music City Center
Karl F. Dean Grand Ballroom A, Level 4
Suhayl Dhib-Jalbut, MD
Professor and Chairman, Department of Neurology
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ
Machteld E. Hillen, MD
Director, Adult Neurology Clinic and Neurology Residency Program
Department of Neurology
Rutgers NJ Medical School
Health Union, LLC
The clinical benefits of early, aggressive treatment in MS have been demonstrated via slower progression of disease and improved patient quality of life. Disease-free status, or “no evidence of disease activity” (NEDA), is now a realistic treatment goal. However, with 15 current FDA-approved disease-modifying therapies (DMTs) available, it is challenging to personalize selection of the optimal agent for each patient.
Achieving New Treatment Goals in Multiple Sclerosis: Strategies for Initial Treatment Selection and Patient Engagement will provide clinicians with current evidence on biomarker development, comparative treatment effectiveness, monitoring, and maintenance regimens. Participants will explore safety and efficacy data for current and emerging DMTs and NEDA treatment goals. Because of the long-term nature of MS management, effective patient engagement is crucial to achieve the best possible outcomes. The activity will also provide physicians with strategies to foster patient engagement within the time constraints of the typical patient visit.
Welcome and Introductions
Applying Current Evidence to Achieve New Treatment Goals
Personalizing Treatment Selection Based on Disease Activity
Optimizing Patient Engagement and Shared Decision-Adherence
Q&A Session and Activity Roundup
This activity is intended for MS specialists, neurologists, nurses, and other healthcare professionals who manage patients with MS.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Recognize the benefits of starting an optimal DMT early enough to achieve the new treatment goal of “no evidence of disease activity” (NEDA)
- Apply current evidence to select a personalized disease-modifying treatment approach with appropriate modifications based on disease activity
- Implement practical strategies for improving patient engagement in management plans
JOINT PROVIDER STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Rockpointe. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Nurses – The CMSC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Physicians–The Potomac Center for Medical Education designates this live activity for a maximum of 1.00 AMA PRA Category I CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test, or evaluation, please email email@example.com.
Nurses – The CMSC designates this activity for 1.0 credit of continuing nursing education (1.0 credits are in the area of pharmacology). For information about the nursing accreditation of this program, please contact the CMSC at firstname.lastname@example.org.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
METHOD OF PARTICIPATION
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME/CE certificate will be emailed within 2 weeks upon submission of a completed evaluation form.
There are no fees associated with this program.
Jointly provided by the Potomac Center for Medical Education, the Consortium of Multiple Sclerosis Centers, and Rockpointe
This program is supported by an educational grant from Sanofi Genzyme.